Abstract: The SWI/SNF chromatin remodeling complexes play a critical role in transcriptional regulation and DNA repair, and their subunits are frequently mutated across various human cancers. Brahma homolog (BRM, SMARCA2) and Brahma-related gene 1 (BRG1, SMARCA4) serve as the mutually exclusive catalytic ATPases of these complexes. The discovery of a synthetic lethal relationship between BRG1 mutations and BRM dependency has driven the development of targeted small-molecule inhibitors. BRM014 and its related analogs are potent, orally active, allosteric dual inhibitors of BRM and BRG1 ATPase activity. This review synthesizes current literature on BRM014 and its precursor series, detailing their pharmacological activity, molecular mechanisms, and structure-activity relationships (SAR). Furthermore, it highlights the role of BRM014 in impairing homologous recombination, sensitizing cancer cells to PARP inhibitors, and activating the cGAS/STING innate immune response. Finally, the review addresses current dose-limiting toxicities and explores future therapeutic perspectives, particularly in combination therapies involving DNA-damaging agents and immunotherapies.
1. Introduction
Aberrant regulation of transcriptional programs through defects in chromatin-remodeling activity is a hallmark of many cancers. The multi-subunit SWI/SNF chromatin-remodeling complexes are mutated in approximately 20% of human cancers [1][2]. These complexes utilize ATP hydrolysis to push and slide nucleosomes along DNA, thereby modulating chromatin accessibility for transcription and DNA repair [2]. The complexes contain one of two mutually exclusive catalytic ATPase subunits: Brahma-related gene 1 (BRG1, also known as SMARCA4) or Brahma homolog (BRM, also known as SMARCA2) [1][2].
Mutations in BRG1 occur frequently in non-small-cell lung cancer (NSCLC), melanoma, and other malignancies. Genetic screening has revealed a synthetic lethal relationship wherein BRG1-deficient cancer cells become exquisitely dependent on the ATPase activity of BRM for survival [1]. This dependency has established BRM as a highly attractive therapeutic target. Consequently, researchers have developed small-molecule catalytic inhibitors, such as BRM014 and its related optimized analogs, which act as dual BRG1/BRM ATPase inhibitors. These compounds serve as critical tools for probing SWI/SNF functions in epigenetics, chromatin remodeling, and DNA double-strand break (DSB) repair [1][2].
2. Pharmacological Activity
Dual BRM/BRG1 inhibitors exhibit robust pharmacological activity both in vitro and in vivo. In cellular assays, these inhibitors downregulate BRM-dependent gene expression, such as KRT80, and demonstrate potent antiproliferative activity in BRG1-mutant cancer models, including lung tumor xenografts and cutaneous melanoma cell lines [1]. In in vivo xenograft models, oral administration of optimized compounds from this series resulted in dose-dependent tumor-growth inhibition and pharmacodynamic modulation of KRT80 mRNA levels [1].
Beyond transcriptional regulation, BRM014 profoundly impacts DNA repair pathways. Treatment with BRM014 impairs the repair of DNA double-strand breaks (DSBs) and inhibits the clearance of γH2AX foci following DNA damage [2]. Specifically, BRM014 reduces the efficiency of homologous recombination (HR) and simultaneously stimulates the use of the more mutagenic non-homologous end joining (NHEJ) pathway [2]. Because of this HR deficiency, BRM014 strongly sensitizes various cancer cells—including U2OS osteosarcoma and MDA-MB-231 triple-negative breast cancer cells—to DSB-inducing chemotherapeutic agents like camptothecin, bleomycin, cisplatin, and etoposide. Importantly, dual inhibition by BRM014 also sensitizes these cells to PARP inhibitors (PARPi) such as olaparib and talazoparib, overcoming the intrinsic PARPi resistance typically observed in cells lacking only BRG1 [2].
3. Molecular Mechanism of Action
BRM014 and its analogs function as allosteric inhibitors of the BRM and BRG1 ATPases. X-ray crystallography studies reveal that these compounds bind to an allosteric pocket in the vicinity of the ATP binding site. The urea moiety of the inhibitor engages in a bidentate hydrogen-bonding interaction that traps the catalytic glutamate residue (Glu852) in an inactive "out" conformation, thereby preventing ATP hydrolysis and subsequent chromatin remodeling [1].
By inhibiting ATPase activity, BRM014 reduces SWI/SNF-mediated chromatin accessibility. In the context of DNA repair, this lack of chromatin remodeling prevents the necessary reduction of nucleosome density at DSB sites. Consequently, the DNA end resection step of homologous recombination is severely impaired, as evidenced by a significant reduction in chromatin-bound Replication Protein A (RPA) and phosphorylated RPA (pRPA) foci [2]. The failure to resect DNA ends blocks HR and forces the cell to utilize the NHEJ pathway [2].
Furthermore, the genomic instability and accumulation of DSBs caused by BRM014 lead to an increased frequency of micronuclei formation. These micronuclei rupture and release DNA into the cytoplasm, which is detected by cyclic GMP/AMP synthase (cGAS). This triggers the cGAS/STING innate immune response pathway, leading to the phosphorylation of NFκB and the subsequent transcriptional upregulation of inflammatory cytokines such as IFNB1, CXCL10, and CCL5 [2].
4. Structure-Activity Relationship (SAR)
The discovery and optimization of the BRM/BRG1 inhibitor series began with a dipyridyl urea scaffold identified through high-throughput screening. Extensive SAR studies highlighted several critical features for binding and potency:
First, the 2-halo-4-substituted pyridine motif is essential for inhibitory activity. While the chlorine atom can be replaced with bromine or fluorine, its presence is strictly required [1]. Second, the central urea linker is absolutely critical; it cannot be replaced by other functional groups, with the sole exception of thiourea, which maintains comparable potency. Structural analysis indicates a strong preference for a flat trans urea conformation, where both N-H groups act as hydrogen-bond donors to trap the catalytic glutamate [1].
The opposite pyridine ring is more tolerant to modification. Substitutions on this ring, such as methyl, difluoromethyl, and trifluoromethyl groups, yielded significant improvements in biochemical potency. Furthermore, the isosteric replacement of this pyridine ring with an isothiazole ring afforded additional potency gains. For example, incorporating an amine or hydroxymethyl group on the chloropyridine alongside the isothiazole modification led to highly potent compounds with excellent cellular activity in BRM-dependent gene-expression assays [1].
5. Current Limitations
Despite the high cellular potency and oral bioavailability of BRM014 and its analogs, their clinical translation faces significant challenges, primarily related to in vivo tolerability. In animal models, attempts to drive sustained pharmacodynamic inhibition were hampered by dose-limiting toxicities. For instance, higher dosing regimens (e.g., 30 mg/kg) resulted in significant body-weight loss and required the exclusion of animals from studies [1].
A major contributing factor to this toxicity is the lack of selectivity between BRM and BRG1. Because these compounds are dual inhibitors, they simultaneously ablate the function of both ATPases. While this dual inhibition is highly effective at killing cancer cells and sensitizing them to DNA damage, it also disrupts the redundant, essential functions of BRM and BRG1 in normal tissues, leading to systemic lethality [1][2].
6. Future Perspectives
The dual functionality of BRM014—disrupting oncogenic transcription and impairing DNA repair—opens several promising therapeutic avenues. For cancers that do not strictly depend on SWI/SNF-mediated oncogene expression (e.g., MYC), BRM014 can be repurposed to induce a homologous recombination deficiency (HRD). This creates a therapeutic window for combination treatments with DSB-inducing chemotherapies or PARP inhibitors, potentially expanding the utility of PARPi beyond BRCA-mutated cancers [2].
Additionally, the ability of BRM014 to activate the cGAS/STING pathway and induce an innate immune response presents a strong rationale for combining SWI/SNF inhibitors with immune checkpoint inhibitors. By increasing tumor immunogenicity through micronuclei formation and cytokine release, BRM014 could prime "cold" tumors for immunotherapy [2].
To overcome current tolerability issues, future medicinal chemistry efforts must focus on developing highly selective BRM inhibitors that spare BRG1. Achieving this selectivity would allow for the exploitation of the synthetic lethal relationship in BRG1-mutant cancers while preserving the essential chromatin-remodeling functions in healthy tissues [1].
